Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Tepotinib in Patients With Solid Cancers Harboring c-MET Amplification or Exon 14 Mutation Who Progressed After Standard Treatment for Advanced/Metastatic Disease

NCT04647838 is registered in ClinicalTrials.gov with Chungbuk National University Hospital as lead sponsor.

NCT NCT04647838
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04647838 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Tepotinib in Patients With Solid Cancers Harboring c-MET Amplification or Exon 14 Mutation Who Progressed After Standard Treatment for Advanced/Metastatic Disease
Lead sponsor
Chungbuk National University Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
January 16, 2020
Completion date
August 31, 2024
Enrollment
100 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

met amplification, met exon 14 skipping mutation, solid tumor